Science and technology

RGF® Environmental Group Initiates Research Project to Enhance Filtration and Inactivation of Radioactive Particulates

Retrieved on: 
Thursday, May 5, 2022
Atmosphere, Second, Weather, Filtration, HEPA, Carbon, Water, GLOBE, PHI, Travel, Power plant engineering, Gas, Boron, Radiation, ISO 9001:2015, School, Journal of Physics: Conference Series, Ultra-low particulate air, FDA, Environment, Industry, Food, Hospital, History, Lists of weapons, PALM, Open-air treatment, Minatec, RGF, Aircraft, Conference, Ozone, Technology, Science and technology, Research, Heart, Port, Political movement, World, Uranium, Medical imaging, Physics, Science

PALM BEACH, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- RGF Environmental Group, Inc. is a world leader in Air Treatment Technologies.

Key Points: 
  • PALM BEACH, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- RGF Environmental Group, Inc. is a world leader in Air Treatment Technologies.
  • True HEPA filtration is widely recognized as a safe, practical and effective technology for cleaning the air.
  • HEPA filtration technology was originally developed during the Second World War to protect scientists working on nuclear weapons.
  • RGF originally designed, built and tested a radiation filter/neutralizer 21 years ago for a multi-billionaire's office in New York after 9/11.

Heura Launches Good Rebel Tech (G.R.T.), a Multidisciplinary Scientific Approach to Redefine Plant-Based Food Manufacturing

Retrieved on: 
Wednesday, May 4, 2022
Food, Beverage, Environment, Retail, Other Technology, Technology, United Kingdom, Food industry, Micronutrient, DHS Science and Technology Directorate, Â, Nature, Colloid, Animal, Food technology, Sale, Protein, Technology, Science and technology, Solution, Transport, CEO, Multimedia, Fine chemical

While theres currently 1.3 billion tons of waste generated each year by the food industry globally, Heuras Good Rebel Tech is spearheading a new and more sustainable food frontier, using non-utilized plant sources in their naturally-occurring structures.

Key Points: 
  • While theres currently 1.3 billion tons of waste generated each year by the food industry globally, Heuras Good Rebel Tech is spearheading a new and more sustainable food frontier, using non-utilized plant sources in their naturally-occurring structures.
  • View the full release here: https://www.businesswire.com/news/home/20220504005193/en/
    Heura, Europes fastest-growing plant-based meat company, today launched Good Rebel Tech (G.R.T.
  • Weve created Good Rebel Tech to pave the way for animal-meat successors that are derived directly from nature using low carbon-footprint technologies.
  • Looking ahead, Good Rebel Tech will be filing its first patents throughout 2022, covering the production of nutritionally superior plant-based products.

Chalk River Facility Becomes First Nuclear Laboratory In Canada to Receive GLP Recognition

Retrieved on: 
Wednesday, April 27, 2022
CNL, BRF, Waste management, Standards Council of Canada, Technology, National Nuclear Laboratory, Standards New Zealand, Heel, Research, Toxicity, TAT, Transport, Food, Histology, Molecular biology, Radiopharmaceutical, Organization, GLOBE, Administered prices, Science and technology, Hematology, Laboratory, Good laboratory practice, Solution, Radiation, Actinium-225, Investment, Food and Drug Administration, Safety, Health Canada, Biology, FDA, AECL, Health, Chalk River Laboratories, GLP, Pharmaceutical industry, Renewable energy, Science

CHALK RIVER, Ontario, April 27, 2022 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canadas premier nuclear science and technology organization, is pleased to announce that the Biology Research Facility (BRF) has become the first nuclear facility in Canada to receive Good Laboratory Practices (GLP) Facility recognition, a designation that brings exciting new opportunities in pre-clinical research to CNL.

Key Points: 
  • CHALK RIVER, Ontario, April 27, 2022 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canadas premier nuclear science and technology organization, is pleased to announce that the Biology Research Facility (BRF) has become the first nuclear facility in Canada to receive Good Laboratory Practices (GLP) Facility recognition, a designation that brings exciting new opportunities in pre-clinical research to CNL.
  • An international standard covering all areas of facility operations, GLP recognition facilitates the acceptance of study results by national and international regulators, including Health Canada and the Food and Drug Administration (FDA) in the United States.
  • AECL is proud that CNL has achieved GLP for the Biological Research Facility at Chalk River Laboratories, commented Dr. Amy Gottschling, Atomic Energy of Canada Limiteds (AECL) Vice-President of Science and Technology.
  • Administered by the Standards Council of Canada, GLP recognition ensures a high degree of quality assurance and data integrity for laboratory research, and enables full traceability and curation of information.

Molecular robots work cooperatively in swarms

Retrieved on: 
Wednesday, April 20, 2022
Veni, vidi, vici, NEDO, DNA, Robotics, Nagoya University, Scientific method, Research, New Energy and Industrial Technology Development Organization, Kansai University, Collection, Transport, Future, New energy, Associate, Kinesin, Columbia University, Ministry, Hokkaido University, Efficiency, Development, Science and technology, List, Environment, MEXT, Workload, Faculty, Culture, McMaster Faculty of Science, Microtubule, Kyushu University, Assistant, Medical device, Beekeeping, 3D printing, Sport, Technology, Science, Education

Swarm robotics is a new discipline, inspired by the cooperative behavior of living organisms, that focuses on the fabrication of robots and their utilization in swarms to accomplish complex tasks.

Key Points: 
  • Swarm robotics is a new discipline, inspired by the cooperative behavior of living organisms, that focuses on the fabrication of robots and their utilization in swarms to accomplish complex tasks.
  • Macro-scale swarm robots have been developed and employed for a variety of applications, such as transporting and accumulating cargo, forming shapes, and building complex structures.
  • However, the DNA and azobenzene used in the molecular machines and the cargo were different, so swarming could be controlled independently of cargo-loading.
  • "In the near future, we expect to see microrobot swarms used in drug delivery, contaminant collection, molecular power generation devices, and micro-detection devices," says Akira Kakugo.

Molecular robots work cooperatively in swarms

Retrieved on: 
Wednesday, April 20, 2022
Veni, vidi, vici, NEDO, DNA, Robotics, Nagoya University, Scientific method, Research, New Energy and Industrial Technology Development Organization, Kansai University, Collection, Transport, Future, New energy, Associate, Kinesin, Columbia University, Ministry, Hokkaido University, Efficiency, Development, Science and technology, List, Environment, MEXT, Workload, Faculty, Culture, McMaster Faculty of Science, Microtubule, Kyushu University, Assistant, Medical device, Beekeeping, 3D printing, Sport, Technology, Science, Education

Swarm robotics is a new discipline, inspired by the cooperative behavior of living organisms, that focuses on the fabrication of robots and their utilization in swarms to accomplish complex tasks.

Key Points: 
  • Swarm robotics is a new discipline, inspired by the cooperative behavior of living organisms, that focuses on the fabrication of robots and their utilization in swarms to accomplish complex tasks.
  • Macro-scale swarm robots have been developed and employed for a variety of applications, such as transporting and accumulating cargo, forming shapes, and building complex structures.
  • However, the DNA and azobenzene used in the molecular machines and the cargo were different, so swarming could be controlled independently of cargo-loading.
  • "In the near future, we expect to see microrobot swarms used in drug delivery, contaminant collection, molecular power generation devices, and micro-detection devices," says Akira Kakugo.

NTT Research Names Dr. Al Emondi Head of Partner Strategy

Retrieved on: 
Tuesday, April 19, 2022
Science, Other Science, Research, General Health, Health, Technology, Other Technology, Other Health, Investigational device exemption, CEO, CIS, CTO, Cryptography, NTT, LLC, MEI, Research, Medicine, Research exemption, DARPA, Creativity, Leadership, PHI, Doctor of Philosophy, Organization, Photonics, Ideation, Program, Neuroscience, Nippon Telegraph and Telephone, Electrical engineering, Growth, NAVWAR, Information, Science and technology, Laboratory, S&T, History, Silicon, Comenius University Faculty of Mathematics, Physics and Informatics, FDA, Multimedia, Name, Syracuse University, Principal investigator, View, Government, Physics, Management, Mobile phone operator, Technology, Atlantic Ocean, Informatics

NTT Research, Inc. , a division of NTT (TYO:9432), today announced it has named Dr. Al Emondi Head of Partner Strategy.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced it has named Dr. Al Emondi Head of Partner Strategy.
  • An experienced organizational and technology leader, Dr. Emondi joined NTT Research in March 2022 on a contract basis as part of its leadership advisory team, with responsibilities that include growth and research partner opportunities, strategic project and program support, partner enablement and value, and research investments.
  • View the full release here: https://www.businesswire.com/news/home/20220419005134/en/
    Were delighted to welcome Dr. Emondi to NTT Research, said NTT Research President and CEO Kazuhiro Gomi.
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.

Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 6, 2022
Science and technology, Pemphigus, LinkedIn, Degenerative disease, Glomerulonephritis, News, Conference, MuSK protein, GLOBE, Technology, Patient, Haemophilia, Pharmaceutical industry, Science

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., President of Science and Technology, will present a pre-recorded company presentation at the 21st Annual Needham Virtual Healthcare Conference, which will become available for on-demand viewing on Tuesday, April 12, 2022 at 3:45 p.m.

Key Points: 
  • PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., President of Science and Technology, will present a pre-recorded company presentation at the 21st Annual Needham Virtual Healthcare Conference, which will become available for on-demand viewing on Tuesday, April 12, 2022 at 3:45 p.m.
  • The pre-recorded presentation will be available on the News and Events section of the Companys website at www.cabalettabio.com .
  • Replays of the presentation will be available on the website for 30 days.
  • Cabaletta Bios headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.

Evolv Technology Awarded U.S. Department of Homeland Security (DHS) SAFETY Act Designation for Evolv Express®

Retrieved on: 
Thursday, March 31, 2022
Technology, Other Defense, Contracts, Homeland Security, Security, Other Technology, Public Policy, Government, Software, Hardware, Defense, Cortex, Â, NASDAQ, Congress, DHS, Express, Transport, Risk, Support Anti-Terrorism by Fostering Effective Technologies Act, Privacy Office of the U.S. Department of Homeland Security, Violence, Radiation Control for Health and Safety Act of 1968, Support, Weapon, SEC, Advanced Cryogenic Evolved Stage, SAFETY, Science, CEO, U.S. Securities and Exchange Commission, U.S. Department of Defense Strategy for Operating in Cyberspace, Private Securities Litigation Reform Act, Terrorism, Prospectus, Artificial intelligence, Industry, Technology, Review, Safety, Securities Exchange Act of 1934, Securities Act of 1933, Machine learning, Student, Phrase, Maritime Transportation Security Act of 2002, Department, TSA, Annual report, QATT, Science and technology, Security (finance), Medical device, Risk management, Entertainment

Evolv Technology (NASDAQ: EVLV, Evolv), the global leader in weapons detection security screening, today announced that Evolv Express , its artificial intelligence (AI)-based weapons detection system, has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT).

Key Points: 
  • Evolv Technology (NASDAQ: EVLV, Evolv), the global leader in weapons detection security screening, today announced that Evolv Express , its artificial intelligence (AI)-based weapons detection system, has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT).
  • The Acting Under Secretary for Science and Technology is the deciding official for current SAFETY Act applications.
  • Evolv Express is the only high-throughput weapons detection screening system to achieve SAFETY Act Designation.
  • Evolv Technology, Evolv Express, Evolv Insights, and Evolv Cortex AI are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions.

Carnegie Mellon Announces 2022 Honorary Degree Recipients

Retrieved on: 
Tuesday, March 22, 2022
Army Reserve, Leadership, Multimedia, Business, Fine art, Alumnus, School, Commencement, Carnegie Mellon University, CEO, PNC Financial Services, Harvard University, CMU, Carnegie Mellon School of Computer Science, View, Robotics, Humanities, Computer science, PNC, United States Army Reserve Command, History, Army Reserve Command, University, Science and technology, Industrial design, Management, Science, Technology

PITTSBURGH, March 22, 2022 /PRNewswire/ -- Carnegie Mellon University today announced an accomplished class of creatives, entrepreneurs, public servants, scholars and technologists who will receive honorary degrees at its 2022 Commencement ceremonies, to be held May 13-15.

Key Points: 
  • PITTSBURGH, March 22, 2022 /PRNewswire/ -- Carnegie Mellon University today announced an accomplished class of creatives, entrepreneurs, public servants, scholars and technologists who will receive honorary degrees at its 2022 Commencement ceremonies, to be held May 13-15.
  • "This year's honorary degree recipients and keynote speakers are among today's most accomplished changemakers, artists and innovators," said CMU President Farnam Jahanian .
  • Honorary degrees are one of the highest distinctions presented to an individual by Carnegie Mellon, and their recipients are a source of inspiration to the Tartans and their families gathered at graduation.
  • For more information regarding this year's Honorary Degree Recipients, visit: https://cmu.is/honorary-degree
    View original content to download multimedia: https://www.prnewswire.com/news-releases/carnegie-mellon-announces-2022-...

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 17, 2022
Research, Oxford BioMedica, Phospholipase A2, A5, Review, Conference, Science and technology, Risk, Entrepreneurship, Form 10-K, U.S. Securities and Exchange Commission, Technology, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Muscle, Glomerulonephritis, Private Securities Litigation Reform Act, COVID-19, IND, Autoantibody, A3, Growth, Infrared spectroscopy correlation table, Program, Society, A1, Patient, Pemphigus, Haemophilia, MPV, Degenerative disease, Security (finance), Food, Toxicity, Fast track (FDA), Nephrology, MuSK protein, GLOBE, Investment, FDA, Coronavirus Scientific Advisory Board (Turkey), Safety, Company, Good manufacturing practice, Myasthenia gravis, Pharmaceutical industry, Vaccine, Animal, Cabaletta, A4, Science, Limited

PHILADELPHIA, March 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

Key Points: 
  • No clear signs of biologic activity were observed in the two lowest cell dose cohorts (20 million and 100 million DSG3-CAART cells).
  • In addition, Cabaletta plans to share additional clinical data updates from the DesCAARTes trial at scientific meetings throughout 2022 and 2023.
  • Received FDA clearance to proceed with manufacturing enhancement at a dose of up to 5.0 to 7.5 billion DSG3-CAART cells.
  • All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.